Evidence check: APOA2 in the context of longevity

APOA2 encodes apolipoprotein A-II, a component of HDL. Some studies (e.g., on rs5082) suggest associations with dietary fat intake, BMI, and insulin resistance – factors that may indirectly influence longevity. However, evidence for a direct lifespan-extending effect is weak and mostly based on observational studies. MyBody-X may include APOA2 variants in their DNA tests, but clinical relevance for longevity is unclear. No randomized controlled trials demonstrate causality. Effect sizes are small and not consistently replicated. Dietary recommendations based on APOA2 genotype (e.g., low-fat diet for risk carriers) are sometimes made in practice, but evidence is mixed. For serious longevity assessment, prioritize better-supported biomarkers (e.g., APOE, FOXO3). Caveat: Direct-to-consumer tests often overstate the importance of single genes.